[Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
D000368:Aged; D001545:Benserazide / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004576:Electromyography; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*
D004338:Drug Combinations; D006834:Hydrazines; D010648:Phenylacetates; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D013973:Thyrotropin-Releasing Hormone; D001545:Benserazide; D013972:Thyrotropin; D006719:Homovanillic Acid